Data in Huntington Disease, Tardive Dyskinesia and Tourette Syndrome
to Be Presented
JERUSALEM--(BUSINESS WIRE)--Jun. 20, 2016--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced new data for SD-809 (deutetrabenazine) tablets will be
presented at the 20th International Congress of Parkinson’s
Disease and Movement Disorders (MDS) in Berlin, June 19-23, 2016.
Teva-sponsored data evaluating SD-809 in patients with chorea associated
with Huntington disease, tardive dyskinesia and tics associated with
Tourette syndrome will be highlighted in clinical, preclinical and
health economics data poster presentations. In addition, Teva will host
a Corporate Symposium entitled, “Emerging Technologies and Therapies in
Movement Disorders,” on Thursday, June 23, 2016 from 1:30 to 2:30 p.m.
CEST.
“There is a significant unmet medical need, as limited options are
currently available for the treatment of neurological disorders such as
Huntington disease, tardive dyskinesia and Tourette syndrome,” said
Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific
Officer at Teva. “Data planned for presentation at this year’s MDS
Congress demonstrates Teva’s commitment to research and helping improve
the lives of patients and caregivers in these severely underserved
patient communities.”
Teva-sponsored data to be presented include:
-
Evaluation of Quality of Life (QoL), Patient- and
Clinician-Reported Outcomes with Deutetrabenazine Treatment of Chorea
in Huntington Disease in First-HD (C. Testa, D. Claassen, D.
Oakes, D. Stamler, V. Sung, S. Frank)
-
Alternatives for reducing chorea in Huntington disease, a long-term
trial (ARC-HD): Updated Week 8 results for the switch cohort (D.
Stamler)
-
Maintenance of balance function in patients with HD treated with
deutetrabenazine, as measured by Berg balance test (BBT) in First-HD (D.
Claassen, D. Oakes, D. Stamler, V. Sung, C. Testa, S. Frank)
-
Evaluating Swallowing Function in Patients with Huntington Disease
Enrolled in the First-HD Study (D. Claassen, S. Frank, V. Sung,
S. Janicki, C. Vaughan, D. Stamler, D. Oakes, C. Testa)
-
A randomized, double-blind, placebo-controlled trial of
deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD) (H.
Fernandez, S. Factor, R. Hauser, J. Jimenez-Shahed, W. Ondo, M.
LeDoux, D. Shprecher, T. Simuni, D. Stamler, K. Anderson)
-
A Randomized Double-blind Placebo- and Positive-Controlled
Crossover Study to Evaluate the Effects of Single Doses of SD-809
(Deutetrabenazine) and Tetrabenazine on the Corrected QT Interval (D.
Stamler, E. Offman, M. Bradbury, L. De Boer)
-
A Pilot Study of SD-809 (deutetrabenazine) in Tics Associated with
Tourette Syndrome (J. Jankovic, J. Jimenez-Shahed, C. Budman,
B. Coffey, T. Murphy, D. Shprecher, D. Stamler)
-
Indirect comparison of tolerability of deutetrabenazine and
tetrabenazine in the First-HD and TETRA-HD trials (D. Claassen,
B. Carroll, L. De Boer, E. Wu, R. Ayyagari, S. Gandhi, D. Stamler)
-
Temporal course of the UHDRS chorea score in Huntington disease (T.
Felong, P. Auinger, S. Gandhi, V. Abler, K. Biglan, S.
Papapetropoulous, C. Venuto, R. Dorsey)
-
Temporal course of the Total Motor Score in Huntington disease (P.
Auinger, T. Felong, S. Gandhi, V. Abler, K. Biglan, S.
Papapetropoulous, C. Venuto, R. Dorsey)
-
Epidemiology and economic burden of falls and fractures in patients
with Huntington's disease (D. Claassen, P. Donga, S.
Rajagopalan, L. De Boer, B. Carroll, S. Gandhi)
About SD-809
SD-809 (deutetrabenazine) is an investigational, oral, small-molecule
inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is being
developed for the treatment of chorea associated with Huntington disease
(HD). Deutetrabenazine has been granted Orphan Drug Designation for the
treatment of HD by the U.S. Food and Drug Administration (FDA). Teva is
also investigating the potential of deutetrabenazine for treating
tardive dyskinesia, for which the FDA has granted a breakthrough therapy
designation, and for tics associated with Tourette syndrome, for which
the FDA has granted orphan status for pediatric use. Deutetrabenazine
uses Teva’s deuterium technology.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva's net
revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U.S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (which
faces competition from orally-administered alternatives and a generic
version); our ability to consummate the acquisition of Allergan plc’s
worldwide generic pharmaceuticals business (“Actavis Generics”) and to
realize the anticipated benefits of such acquisition (and the timing of
realizing such benefits); the fact that following the consummation of
the Actavis Generics acquisition, we will be dependent to a much larger
extent than previously on our generic pharmaceutical business; potential
restrictions on our ability to engage in additional transactions or
incur additional indebtedness as a result of the substantial amount of
debt we will incur to finance the Actavis Generics acquisition; the fact
that for a period of time following the consummation of the Actavis
Generics acquisition, we will have significantly less cash on hand than
previously, which could adversely affect our ability to grow; the
possibility of material fines, penalties and other sanctions and other
adverse consequences arising out of our ongoing FCPA investigations and
related matters; our ability to achieve expected results from
investments in our pipeline of specialty and other products; our ability
to identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the
intellectual property rights of our specialty medicines; the effects of
reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; competition for our generic products, both
from other pharmaceutical companies and as a result of increased
governmental pricing pressures; governmental investigations into sales
and marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal
or third-party information technology systems that adversely affect our
complex manufacturing processes; significant disruptions of our
information technology systems or breaches of our data security;
competition for our specialty pharmaceutical businesses from companies
with greater resources and capabilities; the impact of continuing
consolidation of our distributors and customers; decreased opportunities
to obtain U.S. market exclusivity for significant new generic products;
potential liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that are
not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial talent; any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the
effects of increased leverage and our resulting reliance on access to
the capital markets; potentially significant increases in tax
liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2015 and in our other filings with the U.S. Securities and Exchange
Commission (the "SEC"). Forward-looking statements speak only as of the
date on which they are made and we assume no obligation to update or
revise any forward-looking statements or other information, whether as a
result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005446/en/
Source: Teva Pharmaceutical Industries Ltd.
For Teva Pharmaceutical Industries Ltd.:
IR Contacts:
Kevin
C. Mannix, 215-591-8912
United States
or
Ran Meir, 215-591-3033
United
States
or
Tomer Amitai, 972 (3) 926-7656
Israel
PR
Contacts:
Iris Beck Codner, 972 (3) 926-7687
Israel
or
Denise
Bradley, 215-591-8974
United States
or
Nancy Leone,
215-284-0213
United States